News|Articles|June 26, 2026
5 Essential Capabilities for Decentralized Clinical Trials
Author(s)Quest Diagnostics
Key Takeaways
- Decentralized clinical trials are positioned as a foundational competency as clinical research continues shifting toward broader access and real-world evidence generation.
- Expanded participation is enabled by reducing geographic and logistical barriers for patients, supporting more inclusive enrollment and retention.
Advertisement
As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
2
ACT Brief: Organizational Barriers to Programmatic Recruitment, Scaling Selective Safety Data Collection, and Subcutaneous Alzheimer's Treatment
3
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
4
Selective Safety Data Collection and the Case for Simpler Trials: Q&A with Rob DiCicco, TransCelerate Biopharma
5